重症病毒性肝炎的病死率一般高达80％～90％。全国重症肝炎攻关协作组即使采用优选的综合治疗方案治疗,病死率仍高达54.54％。但自1985年国内陈成伟率先使用胎肝细胞(Fetal Liver Cells,FLC)悬液于临床治疗重症肝炎以来,国内各地众多学者也先后对FLC治疗重症肝炎进行了深入的研究和临床观察。从目前全国各地的报道看,应用FLC治疗重症肝炎,均取得令人鼓舞的疗效,具有极其良好的前景。但 The mortality of severe viral hepatitis is generally as high as 80% to 90%. National Severe Hepatitis Collaborative Group even with the best comprehensive treatment options, the mortality rate is still as high as 54.54%. However, since the first domestic use of Fetal Liver Cells (FLC) suspension in clinical treatment of severe hepatitis, Chen Chengwei has carried out in-depth research and clinical observation on the treatment of severe hepatitis by FLC in 1985. From the current reports all over the country, the application of FLC treatment of severe hepatitis, have achieved encouraging results, with extremely good prospects. but